Payment overview · 2025
General Payments
$475.69
25 reported records · 11 companies
Healthcare provider profile · identity verified
Robert Hammond
Allopathic & Osteopathic Physicians|Family Medicine · VALLEY, AL · NPI 1437682952
Verified facts
What the public records show
CMS Open Payments records show Robert Hammond received $475.69 in general payments during 2025 across 25 reported records.
Novo Nordisk Inc accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Shingrix, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $103.18 | 21.7% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $73.72 | 15.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $61.37 | 12.9% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.37 | 12.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.51 | 8.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.23 | 8.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.61 | 7.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.85 | 3.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.86 | 3.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.91 | 3.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.08 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $475.69 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $73.72 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.37 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $53.96 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.22 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.22 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.73 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.61 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 146 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 200 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 17 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 99 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
146 | 40 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
17 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
99 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
200 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 577 | 109 |
| Gabapentin | Gabapentin | 514 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 487 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 427 | 133 |
| Pantoprazole Sodium | Pantoprazole Sodium | 321 | 112 |
| Alprazolam | Alprazolam | 261 | 49 |
| Lisinopril | Lisinopril | 251 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 250 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 73 |
| Famotidine | Famotidine | 240 | 90 |
| Potassium Chloride | Potassium Chloride | 239 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 221 | 69 |
| Tramadol Hcl | Tramadol Hcl | 218 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 210 | 73 |
| Ozempic | Semaglutide | 200 | 44 |
| Montelukast Sodium | Montelukast Sodium | 191 | 67 |
| Trazodone Hcl | Trazodone Hcl | 191 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 67 |
| Losartan Potassium | Losartan Potassium | 180 | 57 |
| Furosemide | Furosemide | 172 | 60 |
| Omeprazole | Omeprazole | 172 | 57 |
| Valsartan | Valsartan | 156 | 58 |
| Metformin Hcl | Metformin Hcl | 150 | 56 |
| Jardiance | Empagliflozin | 146 | 40 |
| Sertraline Hcl | Sertraline Hcl | 141 | 50 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 140 | 59 |
| Meloxicam | Meloxicam | 140 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 64 |
| Pregabalin | Pregabalin | 124 | 38 |
| Carvedilol | Carvedilol | 113 | 40 |
| Mounjaro | Tirzepatide | 112 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 34 |
| Simvastatin | Simvastatin | 107 | 35 |
| Mirtazapine | Mirtazapine | 106 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 103 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 38 |
| Fluconazole | Fluconazole | 100 | 68 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 99 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 27 |
| Clonazepam | Clonazepam | 92 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 30 |
| Eliquis | Apixaban | 90 | 23 |
| Glimepiride | Glimepiride | 82 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 25 |
| Bupropion Xl | Bupropion Hcl | 80 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 13 |
| Celecoxib | Celecoxib | 77 | 31 |
| Methocarbamol | Methocarbamol | 77 | 31 |
| Trulicity | Dulaglutide | 75 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 22 |
| Allopurinol | Allopurinol | 69 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 21 |
| Metformin Hcl Er | Metformin Hcl | 63 | 23 |
| Linzess | Linaclotide | 58 | 18 |
| Prednisone | Prednisone | 53 | 30 |
| Ezetimibe | Ezetimibe | 52 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 46 |
| Spironolactone | Spironolactone | 48 | 17 |
| Promethazine Hcl | Promethazine Hcl | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 12 |
| Alendronate Sodium | Alendronate Sodium | 46 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 18 |
| Propranolol Hcl Er | Propranolol Hcl | 45 | 14 |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 11 |
| Buspirone Hcl | Buspirone Hcl | 40 | 14 |
| Torsemide | Torsemide | 39 | 11 |
| Levofloxacin | Levofloxacin | 37 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 13 |
| Azelastine Hcl | Azelastine Hcl | 36 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 26 |
| Cilostazol | Cilostazol | 34 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | 12 |
| Azithromycin | Azithromycin | 33 | 31 |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | 16 |
| Clonidine Hcl | Clonidine Hcl | 30 | 13 |
| Atenolol | Atenolol | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | 12 |
| Sucralfate | Sucralfate | 27 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Metolazone | Metolazone | 24 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 21 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | 12 |
| Pentoxifylline | Pentoxifylline | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 13 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | 11 |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Nystatin | Nystatin | 20 | 11 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 17 |
| Naproxen | Naproxen | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 15 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Primidone | Primidone | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $475.69 · 25 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, CAPLYTA, Cologuard Collection Kit, FANAPT, JARDIANCE, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error